Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Announces ReceptoPharm Patent for a Method of Treating Multiple Sclerosis
April 11, 2007

Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its drug discovery division, ReceptoPharm, has filed a patent for a method of treating autoimmune diseases, including Multiple Sclerosis (MS) and Rheumatoid Arthritis.

The patent discusses a method of treatment that uses ReceptoPharm’s lead drug candidate, RPI-78M, to induce gamma-interferon and interleukin-27 (IL-27). IL-27 is a recently discovered and important anti-inflammatory regulator in cells of the immune system.

“We are pleased to announce this important discovery by ReceptoPharm,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Recently, larger biotechnology companies, including Genentech, have shown interest in ways to control this pathway as a means to treat several autoimmune diseases. Some have even proposed the direct use of IL-27 to down regulate the autoimmune process,” he added.

The ReceptoPharm patent provides a new way of controlling autoimmune diseases. Inducing IL-27 and gamma-interferon shut down the inflammation process by influencing the release of another interleukin, IL-17, that is a newly discovered component in maintaining the inflammation and autoimmune process.

“This discovery is significant to our continued research and development, as it identifies the mechanism of action for RPI-78M,” explained Paul Reid, CEO of ReceptoPharm, Inc. “We believe that our drug is the first to induce the expression of IL-27, which represents a novel way to approach the treatment of several autoimmune diseases,” he concluded.

In March, ReceptoPharm received notification of acceptance of its paper, entitled “Alpha-Cobratoxin as a possible therapy for Multiple Sclerosis; a review of the literature leading to its development for this application”, for publication in the Critical Reviews in Immunology special conference issue. In addition, the Company recently announced its nonbinding letter of intent with Nanogene Biotechnology to create a joint venture in China aimed at developing its antiviral drug, RPI-MN, for the Chinese market.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The recently filed ReceptoPharm patent for a method of treating autoimmune diseases should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy


June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics